Marker Therapeutics Inc (MRKR)

[Phantom Lord]

This is just an update on upcoming events that I already posted. This post is copied and pasted form a previous post but updated with new information we have received since the last post (HERE) from 1/8/2019. Updates in bold.

There are clickable links in each post to the previous on so if you click on the link above you should be able to click back to my initial post. That first post has clickable links to all of Marker's trials which are at the end of this post.

Anytime:

1. The DoD funded trial of TPIV 110 in DCIS should begin anytime now. The funding was already secured so now we are just waiting for Mayo to start the trial. Nomura estimated sometime in 2019.
2. DoD gave Mayo a grant to fund a PII trial in TPIV 110 combined w/ Herceptin in HER2/neu positive breast cancer patients. HERE is the PR. This will be fully run by Mayo on their timeline so I don't expect it to be quick. Either way, it's fully funded.
3. IIRC we were supposed to get interim data from Tapimmune sponsored phase II trial of TPIV 200 in patients w/ TNBC. I could have completely missed it but I don't remember seeing this. I've got an email out to the company for clarification.

Q1 2019:

This is looking pretty bare from what I am seeing. Maybe a good time to add to positions if the SP dips due to lack of news barring any surprises. Presentation at ASBMT this week on February 20th and 23rd. Three oral presentations and one poster presentation. HERE is the PR with links to the abstracts. I'm not sure if we really get a bump here but this is an actual medical conference so we will get more than just a "corporate overview."

Q2 2019:

2. Completion of TPIV200 & Durvalumab combo trial w/ $AZN in patients w/ ovarian cancer. This trial had a data readout and will not continue any further.
3. Primary completion of ADSPAM trial in AML.
4. Primary completion of TACTAM trial in multiple myeloma.
5. Primary completion of STELLA trial in acute lymphoblastic leukemia.

*These are just primary completion dates. It does not mean we will 100% get any data or information. This is just the date that last participant was examined to collect final data.

2H 2019:

I’ve lumped Q3 & Q4 together as I’m going to speculate a bit since there aren’t a lot of set dates in this timeframe. Given all the completion dates in Q2 we could hear more information as to the next trials, i.e. PII & PIII trials. With the primary completion of ADSPAM, TACTAM, & STELLA I would not be surprised to see our participation at ASH. This usually takes place in the beginning of December. For those that don’t know this is a MAJOR conference, think ASCO. Obviously, speculation but I know the company is hoping to have a presentation accepted.

Interim data from Tapimmune sponsored trial of TPIV 200 in patients w/ Ovarian cancer. Should see interim data by year end 2019. This was pushed back from an initial anticipated readout in Q2

Nomura has a list of all potential upcoming events and catalysts in their research report as well. If anyone would like to read it send me your email and I will gladly send you their report.

All trials referenced above, along with the rest of Marker’s trials, are below. My first post HERE has clickable links to view all of these trials.


ADSPAM – AML: NCT02494167

TACTAL – Leukemia: NCT01333046

TACTAM – Multiple Myeloma: NCT02291848

TACTIC – Breast Cancer: NCT03093350

TACTOPS – Pancreatic Cancer: NCT03192462

STELLA – Acute Lymphoblastic Leukemia: NCT02475707

TPIV 200 for ovarian: NCT02978222

TPIV 200 for TNBC: NCT02593227

Combination trial of TPIV 200 & Durvalumab for ovarian: NCT02764333

TPIV 200 for TNBC funded by DOD w/ Mayo Clinic: NCT03012100

Good Luck everyone!